Gertrude B. Elion

Lore & Background

Elion was born in New York City to Lithuanian and Polish Jewish immigrant parents. Her family lost their wealth after the Wall Street Crash of 1929. She graduated from Walton High School at age 15 and earned a degree in chemistry summa cum laude from Hunter College in 1937, where she was Phi Beta Kappa. Unable to find a paying research job because she was a woman, she worked as a secretary, high school teacher, and in an unpaid chemistry lab before earning her M.Sc. from New York University in 1941. Her fifteen financial aid applications for graduate school were turned down due to gender bias. She later pursued a doctorate part-time but gave it up when required to attend full-time; she never obtained a formal Ph.D.

In 1944, Elion became an assistant to George H. Hitchings at Burroughs-Wellcome. Hitchings was developing drugs by imitating natural compounds to trick pathogens. Elion synthesized anti-metabolites of purines, leading to the anti-cancer drugs tioguanine and mercaptopurine in 1950. She later headed the department of experimental therapy at Burroughs Wellcome from 1967 to 1983. After retiring in 1983, she continued working almost full-time, contributing to the development of AZT and earlier purine analogs. She never married or had children; her hobbies included photography, travel, opera, and ballet.

Reader's Guide

Gertrude B. Elion's significance lies in her pioneering use of rational drug design, which shifted pharmaceutical development from trial-and-error to a targeted approach based on biochemical differences between human cells and pathogens. This method produced drugs for leukemia, malaria, lupus, hepatitis, arthritis, gout, organ transplant rejection (azathioprine), and herpes (acyclovir), as well as the first widely used anti-AIDS drug, AZT. Despite facing gender discrimination that blocked her from graduate research positions and a doctoral degree, she became the fifth woman Nobel laureate in Medicine and one of only a handful without a Ph.D. Her legacy includes mentoring students at Duke University, publishing over 25 papers with them, and encouraging women in science. She was elected to the National Academy of Sciences in 1990 and received the National Medal of Science in 1991.

Did You Know?

• Elion never obtained a formal Ph.D., but was later awarded honorary doctorates from Polytechnic University of New York (which later merged into NYU Tandon School of Engineering) and Harvard University.
• She was the only woman honored with a Nobel Prize in 1988.
• Her grandfather's death from stomach cancer when she was 15 inspired her to pursue a career in science and medicine.
• She contributed to earlier purine analogs that laid the groundwork for drugs like nelarabine, which was developed after her death and approved in 2005.

A Prolific Drug Developer

Gertrude B. Elion stands as one of the most prolific figures in twentieth-century pharmaceutical science. Across her career, she contributed to the creation or development of at least five landmark medications that continue to save lives. Her work spanned antiviral therapy, immunosuppression, anti-parasitic treatment, oncology, and antiretroviral medicine. She helped bring aciclovir into clinical use for herpes simplex virus, chickenpox, and shingles. She made foundational contributions to AZT, one of the earliest antiretroviral drugs deployed against HIV/AIDS. She initially developed pyrimethamine, marketed as Daraprim, as a malaria treatment before it found additional use against toxoplasmosis and isosporiasis. Alongside George H. Hitchings, she discovered mercaptopurine for leukemia and autoimmune conditions, and together they synthesized azathioprine in 1957. The sheer range of therapeutic areas she touched—viral, parasitic, autoimmune, and malignant disease—marks her as a uniquely versatile figure in the history of medicine.

The Hitchings Partnership

Two of Elion's most celebrated achievements emerged from her long collaboration with George H. Hitchings. Together, the pair discovered mercaptopurine, a medication now prescribed for acute lymphocytic leukemia, chronic myeloid leukemia, Crohn's disease, and ulcerative colitis. Their partnership also produced azathioprine, which they first synthesized in 1957. Azathioprine became an immunosuppressive agent used to manage rheumatoid arthritis, granulomatosis with polyangiitis, Crohn's disease, and ulcerative colitis, and it plays a critical role in preventing organ rejection in kidney transplant patients. The breadth of conditions addressed by these two drugs—ranging from blood cancers to chronic inflammatory bowel disease to post-transplant care—underscores how foundational the Hitchings-Elion work became to modern pharmacology. Their joint discoveries demonstrated that targeted interference with cellular processes could yield treatments effective across an astonishingly wide clinical spectrum, a principle that continues to guide drug design today.

Treating a Spectrum of Disease

Few scientists in the history of medicine can claim contributions to so many distinct therapeutic fields as Gertrude B. Elion. Her antiviral work on aciclovir gave clinicians a tool against herpes simplex virus, chickenpox, and shingles—conditions that had long lacked effective pharmacological intervention. In the realm of parasitic disease, her initial development of pyrimethamine as an antimalarial agent later expanded to treat toxoplasmosis and isosporiasis. Her oncology contributions, particularly mercaptopurine, offered treatment for acute lymphocytic and chronic myeloid leukemia. In autoimmune medicine, both mercaptopurine and azathioprine became cornerstones for managing Crohn's disease, ulcerative colitis, rheumatoid arthritis, and granulomatosis with polyangiitis. Perhaps most dramatically, her foundational role in developing AZT placed her at the origin of the antiretroviral era, providing one of the first medications to prevent and treat HIV/AIDS. This extraordinary portfolio—spanning viral, parasitic, malignant, and autoimmune pathology—reflects a career defined by versatility and deep impact.

Recognition and Place in Scientific History

Gertrude B. Elion's contributions earned her the Nobel Prize, a distinction that cemented her place among the most celebrated scientists of the twentieth century. Her work is consistently highlighted in listings of inventions and discoveries in which women played a major role, underscoring the significance of her achievements within the broader narrative of female scientific leadership. In the pharmaceutical field specifically, her name appears alongside other pioneering women such as Tu Youyou, who discovered artemisinin for malaria, and Flossie Wong-Staal, who first cloned HIV and mapped its genes. Elion's foundational contributions to AZT connect her legacy directly to the HIV/AIDS research community. The recognition she received was not merely for a single breakthrough but for a sustained body of work that reshaped how medicine treats viral infections, parasitic diseases, cancers, and autoimmune disorders. Her Nobel Prize stands as a testament to the transformative power of her research and to the lasting importance of her partnership with George H. Hitchings in advancing rational drug design.